DESTINY-Breast06 Efficacy Surpasses SOC in HER2-Low/Ultralow Breast Cancer

News
Video

Findings from DESTINY-Breast06 showed a PFS of 13.2 months for patients given T-DXd for HER2-low or ultralow breast cancer.

Aditya Bardia, MD, MPH, FASCO, highlighted the main efficacy results observed in the phase 3 DESTINY-Breast06 trial (NCT04494425).1 Results from this trial led to the approval of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for patients with unresectable or metastatic HER2-low or ultralow breast cancer who have previously received 1 prior line of endocrine therapy in the metastatic setting.2

Topline results from the trial showed a median progression-free survival (PFS) for patients with HER2-low disease of 13.2 months in the T-DXd arm and 8.1 months in the chemotherapy arm (HR, 0.62; 95% CI, 0.51-0.74; P <.0001). For those with HER2-ultralow disease, it was 13.2 months vs 8.3 months (HR, 0.78; 95% CI, 0.50-1.21). Finally, those in the intent-to-treat population had a median PFS of 13.2 months vs 8.1 months (HR, 0.63; 95% CI, 0.53-0.75; P <.0001).

Bardia, professor in the Department of Medicine, Division of Hematology/Oncology, and Director of Translational Research Integration at the University of California Los Angeles Health Jonsson Comprehensive Cancer Center, also commented on the most common treatment-related adverse effects with T-DXd, which included nausea, myelosuppression, and pneumonitis.

Transcript:

In DESTINY-Breast06, T-DXd was superior to standard chemotherapy with both capecitabine as well as taxanes for patients with metastatic hormone receptor–positive breast cancer. The median PFS was [approximately 13.2] months, so more than a year in terms of median PFS. Most [median PFS outcomes are approximately] 8 months with standard chemotherapy, so a significant improvement in PFS was seen with T-DXd in this setting.

There are 3 important [adverse] effects [AEs] to remember with T-DXd. The first one is nausea, which is the most common [AE] seen with T-DXd. Generally, we recommend primary prophylaxis with a 3-drug antiemetic regimen. Usually, that’s quite effective. In breakthrough instances, you can use olanzapine [Zyprexa]. The second [AE] is myelosuppression. It can cause neutropenia as well as thrombocytopenia, so it’s important to monitor the counts. The third [AE] is a rare but known [AE] of T-DXd, which is pneumonitis. It’s important to monitor for pneumonitis when you’re getting restaging scans, not only looking at efficacy, but also evidence of pneumonitis, so you can intervene early and prevent this from increasing.

References

  1. Curigliano G, Hu X, Dent RA, et al. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): primary results from DESTINY-Breast06 (DB-06). J Clin Oncol. 2024;42(suppl 17):LBA1000. doi:10.1200/JCO.2024.42.17_suppl.LBA1000
  2. Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies. News release. FDA. January 27, 2024. Accessed January 27, 2024. https://tinyurl.com/5n8ab8sk

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content